Home Drug Codes J Codes J2329 · BRIUMVI
Updated July 1st, 2026

BRIUMVI J Code: J2329

Injection, ublituximab-xiiy, 1mg

Login to unlock all benchmarks

Q4 2026 Medicare Payment Limit for J2329, effective October 1, 2026: $71.089 per HCPCS billing unit, down 1.6% from $72.239. From CMS's final file.

?
Medicare Payment Limit ?
$72.239
/ HCPCS billing unit · Q3 2026
APC Payment Limit ?
$72.239
/ HCPCS billing unit · APC 9149
ASP ?
$•••.••
Login to view
WAC · AWP ?
$•••.••
Login to view
NDCs Crosswalked ?
1
View NDC crosswalk →

Drug & Product Overview

HCPCS Descriptor Injection, ublituximab-xiiy, 1mg
HCPCS Added Date July 1, 2023
Manufacturer TG Therapeutics
Route of Administration Intravenous
Generic Status Single-Source; Branded
Dosage Type Single-Dose
Dosage Form Injection, Solution, Concentrate

About BRIUMVI

Briumvi is a medication aligned to the HCPCS J Code: J2329 for billing, pricing, and reimbursement purposes in the United States. It is a Neurology drug administered via the intravenous route and manufactured by TG Therapeutics.

According to CMS Drug Use Information: This medication is used to treat multiple sclerosis (MS). Ublituximab is not a cure for MS but it is thought to help by preventing immune system cells (lymphocytes) from attacking the nerves in your brain and spinal cord. Ublituximab belongs to a class of drugs known as monoclonal antibodies. It helps decrease the number of episodes of disease worsening (relapses) and may prevent or delay disability.

Disclaimer: This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your healthcare professional.

NDC Code Information

Based on publicly available CMS files. The list of NDCs below is not exhaustive.

NDC Code Drug Manufacturer Billing Units / Pkg Package Size
73150-0150-06 Briumvi TG Therapeutics, Inc. 150 150 MG / 6 ML
Login for the full NDC crosswalk View pricing, complete NDC-to-HCPCS alignments, and package details.
Login →

BRIUMVI Pricing & Reimbursement

J2329 Private Payer Reimbursement
$70.57 / HCPCS unit as of Jan 2026

National median reimbursement across major commercial payers.

Create an account on PayerPrice for more information →
UnitedHealthcare, BlueCross BlueShield, Aetna, Cigna

Historical Graphing and Billing Calculator

per HCPCS unit
As of Q3 2026

BRIUMVI Claims Performance

Claims from Jan 2026 – Aug 2026
Claim Denial Rate 18.07%
Avg. Days to File 8.6days
Avg. Days to Pay 24.4days

Real-world claims performance from FocalPoint, OnPoint Oncology's reimbursement analytics platform, with claims data accrued at the clearing house level.

Explore J2329 claims analytics on FocalPoint →
OnPoint Oncology

BRIUMVI CPT Administration Codes

The below list of CPT codes is intended for informational purposes only and may not be exhaustive. CPT® codes and descriptions are copyright American Medical Association (AMA). All rights reserved.

CPT Code Description
96413 Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug
96415 Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)
JW / JZ modifiers apply

CMS has identified Briumvi (J2329) as a HCPCS code with single-dose containers. Therefore, the JW/JZ wastage modifiers could be required for billing purposes. Wastage billing guide →

BRIUMVI Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

relapsing forms of multiple sclerosis (clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease)
Drug Class
CD20-directed Antibody Interactions [MoA]CD20-directed Cytolytic Antibody [EPC]

Login for BuyandBill.com Analytics

Unlock deeper insights with BuyandBill’s Comparative Report!

  • Compare ASP, WAC, and AWP across drugs.
  • Visualize Drug Price Movement Over Time
  • Tailor reports to drug class, manufacturer, or HCPCS Code.
  • Compare Biosimilar and 505(b)(2) products.

Frequently Asked Questions

Is there an available Briumvi billing and coding guide?
Billing and coding information for BRIUMVI can be found through TG THERAPEUTICS, INC.. Visit Here →
Are there any available Briumvi patient assistance programs?
BRIUMVI patient assistance information can be found through TG THERAPEUTICS, INC.. Visit Here →
Where can I find Briumvi prescribing information?
BRIUMVI prescribing information can be found at the link below: Visit Here →
Where can I find Briumvi side effect information?
Information regarding BRIUMVI's side effects can be found at MedlinePlus Visit Here →
Does billing BRIUMVI require JZ/JW wastage modifiers?
CMS has identified BRIUMVI(J2329) as a HCPCS code with single-dose containers. Therefore, the JW/JZ wastage modifiers could be required for billing purposes. See CMS guidelines on use of the JZ and JW wastage modifiers below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.